Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A-Reference-Cited by-同舟云学术

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A

Published:2022-10-21 Issue:1 Volume:29 Page:90-99
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Schmitt Christophe¹,Mancuso Maria Elisa²,Chang Tiffany³⁴,Podolak‐Dawidziak Maria⁵,Petry Claire¹,Sidonio Jr Robert⁶,Yoneyama Koichiro⁷,Key Nigel S.⁸,Niggli Markus¹,Lehle Michaela¹,Peyvandi Flora⁹¹⁰,Oldenburg Johannes¹¹

Affiliation:

1. Department of Clinical Pharmacology F. Hoffmann‐La Roche Ltd Basel Switzerland

2. IRCCS Humanitas Research Hospital Center for Thrombosis and Hemorrhagic Diseases Rozzano Milan Italy

3. Genentech, Inc. South San Francisco California USA

4. Spark Therapeutics, Inc. Philadelphia Pennsylvania USA

5. Department of Haematology Blood Neoplasms and Bone Marrow Transplantation Wroclaw Medical University Wrocław Poland

6. Children's Healthcare of Atlanta Emory University Atlanta Georgia USA

7. Chugai Pharmaceutical Co., Ltd Tokyo Japan

8. Department of Medicine and Blood Research Center University of North Carolina Chapel Hill North Carolina USA

9. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Milan Italy

10. Department of Pathophysiology and Transplantation Università degli Studi di Milano Milan Italy

11. Universitätsklinikum Bonn Bonn Germany

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14679

Reference29 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. WFH Guidelines for the Management of Hemophilia, 3rd edition

3. Haemophilia and Joint Disease: Pathophysiology, Evaluation, and Management

4. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

5. Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A;Journal of Thrombosis and Haemostasis;2024-07

2. Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies;Haemophilia;2024-03-13

3. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies;Research and Practice in Thrombosis and Haemostasis;2024-02

4. Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks;Research and Practice in Thrombosis and Haemostasis;2024-01

5. Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective;Saudi Pharmaceutical Journal;2023-12